NCT03039751View on ClinicalTrials.gov

Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

October 19, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Refractory Angina PectorisGene TransferCoronary Artery Disease
Interventions
DRUG

AdvVEGF-D

AdvVEGF-D will be injected into 10 sites of the myocardium

DRUG

Control Rx

Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium

Trial Locations (2)

Unknown

Rigshospitalet, Copenhagen

Kuopio University Hospital, Kuopio

Sponsors
All Listed Sponsors
collaborator

Queen Mary University of London

OTHER

collaborator

University College, London

OTHER

collaborator

Medical University of Vienna

OTHER

collaborator

Servicio Madrileño de Salud, Madrid, Spain

OTHER

collaborator

FinVector Vision Therapies Oy

UNKNOWN

collaborator

Śląski Uniwersytet Medyczny w Katowicach

UNKNOWN

collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Euram Limited

UNKNOWN

lead

Kuopio University Hospital

OTHER

NCT03039751 - Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris | Biotech Hunter | Biotech Hunter